Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Is The Predicted Market Size Of The Gastric Cancer Drugs Industry By 2029?
The market size for gastric cancer drugs has witnessed a robust expansion in recent years. The growth is predicted to escalate from $4.41 billion in 2024 to $4.9 billion in 2025, registering a compound annual growth rate (CAGR) of 11.2%. Factors contributing to this growth in the past can be traced back to increased investment in pharmaceutical research and development, rise in healthcare spending, significant economic progress in budding markets, and a swift increase in the older demographic.
In the coming years, the market for gastric cancer medications is predicted to experience quick expansion, anticipating a culmination of $7.35 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 10.7%. Numerous factors have led to this estimated growth, including an increase in gastric cancer incidents, a robust pipeline of potential drugs, heightened levels of healthcare spending, growing mergers and collaborations, a larger aged population, and updates to FDA rules to smooth the progress of biologic drug production. The forecast period is marked by key movements such as strategic partnerships to expand product ranges, joint ventures with other firms or governmental entities, raising the quantity of pipeline research to generate new gastric cancer drugs, the incorporation of AI technologies to lower R&D expenses, the creation of new-generation biologics and the application of CRISPR-cas9 technology in the development of new pharmaceuticals.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp
What External And Internal Drivers Are Influencing The Gastric Cancer Drugs Market?
The rising instances of obesity and smoking have contributed to an upsurge in the number of gastric cancer patients. The habit of tobacco consumption and adherence to an unhealthy diet are key risk factors for stomach cancer. As reported by the Government Digital Service of the UK in May 2023, it was predicted that 25.9% of individuals in England (those aged 18 years and above) were obese in 2022–2022, an increase from 25.2%. This escalation in the number of gastric cancer cases instigates the growth of the market for gastric cancer drugs.
What Are The Primary Segmentation Parameters In The Gastric Cancer Drugs Market?
The gastric cancer drugs market covered in this report is segmented –
1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Subsegments:
1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies
2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab
3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications
Which Emerging Trends Are Reshaping The Gastric Cancer Drugs Market Landscape?
Numerous organizations in the gastric cancer drugs market are devising advanced solutions, including anti-PD-1 therapies, to boost therapeutic effectiveness and refine patient outcomes. Anti-PD-1 therapy is an immunotherapy form that aims at the programmed cell death protein 1 (PD-1) receptor located on immune cells. One such example is in November 2023 when Merck & Co., Inc., a pharmaceutical firm based in the US, attained approval from the US federal agency dedicated to public health protection, the Food and Drug Administration (FDA), for KEYTRUDA (pembrolizumab). Approximated for use in treating gastric cancer, KEYTRUDA (pembrolizumab) is recommended as a front-line treatment for patients suffering from locally advanced, non-resectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This particular recommendation is for usage in conjunction with trastuzumab, plus fluoropyrimidine and platinum-based chemotherapy. The approval for this indication has been expedited given its impact on tumor response rate and the response duration.
Who Are The Dominant Players In The Gastric Cancer Drugs Market Today?
Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
What Are The Emerging Regional Trends Driving The Gastric Cancer Drugs Market?
North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
